SuperworthLifeMD LFMD
- Market cap
- $102.7M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- n/m
- one or more of the four quarters through 2026-06-30 missing
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Net margin
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Free cash flow yield
- −10.7%
LifeMD's trailing earnings are negative, so it has no PE.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $38.6M+23% | $44.9M+60% | $44.1M+33% | $50.7M+41% | $53.3M+38% | $59.5M+33% | $50.9M+15% | $49M−3% | $60.2M+13% | n/a | $50.2M−1% | $47.3M−4% | |
| Cost of revenue | $4.8M+1% | $5.4M+32% | $4.6M+9% | $5M+11% | $5M+5% | $9.4M+76% | $8.1M+77% | $6.8M+36% | $7.4M+48% | n/a | $5.9M−27% | $5.3M−23% |
| Gross profit | $33.8M+27% | $39.5M+64% | $39.5M+37% | $45.6M+45% | $48.3M+43% | $50.1M+27% | $42.8M+8% | $42.2M−8% | $52.8M+9% | n/a | $44.2M+4% | $42M−0% |
| SG&A | $33.2M+12% | $36M+35% | $39.5M+45% | $44.9M+42% | $44.7M+35% | $45.8M+27% | $36.6M−7% | $36.6M−19% | $46.1M+3% | n/a | $45.1M+23% | $41.7M+14% |
| −$4.6M−35% | −$2.2M−79% | −$6.2M+116% | −$6.3M+29% | −$4M−13% | $1M | −$1.2M−81% | −$2.3M−63% | −$2M−51% | n/a | −$8.9M+656% | −$7.1M+204% | |
| Interest expense | $713.8K+440% | $622.7K−26% | $477.7K+81% | $531.5K−47% | $558.6K−22% | $614.1K−1% | $463.6K−3% | $660.8K+24% | $262.5K−53% | n/a | −$56.5K | −$45.7K |
| Pre-tax income | −$5.3M | −$2.8M | n/a | n/a | −$4.6M−14% | $36.5M | −$1.6M | −$3M | −$3.4M−26% | n/a | −$8.9M+439% | −$7.1M+136% |
| n/a | n/a | n/a | n/a | $232.5K | $169.5K | n/a | n/a | $169.1K−27% | n/a | n/a | n/a | |
| Net income | −$6.1M−16% | −$3.7M−69% | −$6.8M+69% | −$6.9M+2% | −$4.7M−24% | −$4.9M+32% | −$183.8K−97% | −$1.6M−76% | −$3.8M−18% | $20M | −$8.9M+4728% | −$7.1M+337% |
| −$0.20−23% | −$0.12−70% | −$0.19+27% | −$0.19−17% | −$0.13−35% | −$0.14+17% | −$0.02−90% | −$0.05−74% | −$0.10−23% | $0.41 | −$0.20+900% | −$0.16+220% | |
| 34.5M+11% | 36.7M+17% | 39.2M+24% | 41.3M+27% | 42M+22% | 42.2M+15% | 43.1M+10% | 44.4M+8% | 46.2M+10% | 46.8M+11% | 47.3M+10% | 47.8M+8% |
EPS, diluted: 14 periods, Q4 FY12 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 13 periods, Q4 FY12 to Q4 FY24: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q4 FY25: share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Healthcare nearest LifeMD's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| LFMDLifeMD | $102.7M | n/m | 82.6× | n/m | n/m | n/m | |
| KEQUKewaunee Scientific | $94.9M | 11.9× | 13.7× | 0.3× | +5% | 3.0% | |
| ICCCImmucell | $93.1M | 128× | 44.0× | 3.0× | +8% | 2.6% | |
| LFVNLifevantage | $73.4M | 14.7× | 19.6× | 0.4× | −20% | 2.8% | |
| SPROSpero Therapeutics | $64.6M | 10.1× | 9.5× | 1.4× | −3% | 15.7% | |
| APTAlpha Pro Tech | $56.7M | 13.6× | 14.8× | 0.9× | +6% | 6.8% | |
| PDEXPro DEX | $199.3M | 15.1× | 16.6× | 2.6× | +16% | 17.6% | |
| PLXProtalix BioTherapeutics | $205.5M | 11.1× | 34.2× | 2.5× | +30% | 23.5% | |
| NATRNatures Sunshine Products | $213.8M | 12.0× | 20.6× | 0.4× | +7% | 3.7% | |
| ATNMActinium Pharmaceuticals | $47.8M | 4.2× | 3.1× | n/m | n/m | n/m | |
| ELMDElectromed | $220.6M | 20.1× | 29.0× | 3.0× | +15% | 15.3% | |
| Peer median | $94M | 12.8× | 18.1× | 1.4× | +7% | 6.8% |
More on LifeMD
Each number over time
- PE ratio
- Price to sales ratio
- Price to free cash flow
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Its groups
About
- Industry
- Medical - Care Facilities
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .